Macrophage Pharma Ltd has appointed Michael Moore as non-executive chairman to help oversee the clinical development of the company’s small molecule drugs targeting macrophages. Dr Moore is currently a non-executive director of Mission Therapeutics Ltd, where he was the founder chairman. He was previously chief executive of Piramed Ltd, acquired by Roche in 2008. As an academic, Dr Moore held positions at the Paterson Institute for Cancer Research and the University of Manchester Medical School.
Macrophage announced the appointment on 11 April 2018.
Copyright 2018 Evernow Publishing Ltd.